Cansortium Financial Statements From 2010 to 2024
| CNTMF Stock | USD 0.07 0.01 6.41% |
Check Cansortium financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cansortium's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cansortium financial statements analysis is a perfect complement when working with Cansortium Valuation or Volatility modules.
Cansortium |
Cansortium OTC Stock Operating Margin Analysis
Cansortium's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cansortium Operating Margin | 0.08 % |
Most of Cansortium's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cansortium is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Cansortium has an Operating Margin of 0.0755%. This is 100.22% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The operating margin for all United States stocks is 101.37% lower than that of the firm.
Cansortium Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cansortium's current stock value. Our valuation model uses many indicators to compare Cansortium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cansortium competition to find correlations between indicators driving Cansortium's intrinsic value. More Info.Cansortium is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cansortium's earnings, one of the primary drivers of an investment's value.About Cansortium Financial Statements
Cansortium stakeholders use historical fundamental indicators, such as Cansortium's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cansortium investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cansortium's assets and liabilities are reflected in the revenues and expenses on Cansortium's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cansortium. Please read more on our technical analysis and fundamental analysis pages.
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida. Cansortium operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Cansortium OTC Stock
Cansortium financial ratios help investors to determine whether Cansortium OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansortium with respect to the benefits of owning Cansortium security.